logo
Pathophysiology and Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS): A Narrative Review

J. Narayanan1*, R. Sridevi1, V. Chitra1, V. Manimaran2, T. Tamilanban1

1Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, India

2Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, India

*For Correspondence

narayanj@srmist.edu.in

Publication Date: October 09, 2024
DOI: 10.5281/zenodo.13864703
Read Abstract

A complicated neurodegenerative disease, amyotrophic lateral sclerosis (ALS) mostly affects motor neurons, resulting in a gradual weakening and atrophy of muscles. This review focuses into the pathophysiology of amyotrophic lateral sclerosis (ALS), providing insight on the complex genetic and molecular pathways at work and the ways in which it overlaps with frontotemporal dementia. Oxidative stress, excitotoxicity, mitochondrial dysfunction, disruption of axonal transport, neuroinflammation, DNA damage, and poor protein homeostasis are key pathological characteristic features of amyotrophic lateral sclerosis (ALS). Important hereditary factors include mutations in genes such as SOD1, FUS, and C9ORF72. About 15% of amyotrophic lateral sclerosis (ALS) patients also show signs of frontotemporal dementia, in addition to the characteristic motor symptoms and cognitive and behavioral abnormalities. The condition is characterized by aberrant TDP-43 or FUS protein aggregates, and the C9ORF72 gene mutation is the most prevalent genetic component. Physical therapy, dietary therapies, and respiratory support are all parts of the multidisciplinary care that is currently available to patients in an effort to reduce symptoms and enhance their quality of life. Gene therapies and novel pharmacological medicines that target specific disease pathways are among the novel treatments being researched. In order to address the complex nature of amyotrophic lateral sclerosis (ALS) and enhance patient outcomes, the field is shifting towards early intervention techniques and personalized medication.

Keywords

Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia, C9ORF72 Gene, Neuroinflammation, ALS Therapy

Download PDF